Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine in Lower Extremity Revascularization
NCT05992896Phase 4Terminated
- Sponsor
- Mayo Clinic
- Start
- Sep 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bupivacaine extended release liposome injection in Peripheral Arterial Disease (PAD), sponsored by Mayo Clinic. Started Sep 2023; status: terminated.
02
Drugs
bupivacaine extended release liposome injection
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT05992896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05992896.